Bergen, Norway, 23 May 2018 - The board of directors in BerGenBio ASA (the "Company") (OSE:BGBIO) has granted options to primary insiders.
The annual general meeting in the Company at 14 May 2018 approved the share options program. Options granted under the option program is vested over a three-year period and each option, when exercised, will give the right to acquire one share in the Company.
A total of 385,027 share options were granted at an exercise price at 46.70, of this the following was granted to primary insiders (total holdings of share options following this grant):
Richard Godfrey - CEO: 122,484 (1,067,484)
Rune Skeie - CFO: 24,090 (24,090)
James B. Lorens - CSO: 10,707 (710,707)
Murray Yule - CDO: 40,797 (190,797)
Anthony Brown - Director of research: 26,499 (176,499)
Endre Kjærland - Associate Director of IP and Contracts: 15,225 (85,225)
Julia Schoelermann - Associate Director of Business development: 15,418 (80,418)
David R. Micklem - Director of Diagnostics & Biomarkers: 11,949 (236,949)
-End-
Contacts
Richard Godfrey
CEO, BerGenBio ASA
ir@bergenbio.com
+47 917 86 304
Rune Skeie
CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.